Effects of Transcutaneous Vagus Nerve Stimulation on Pain and Brain Activity in Healthy Adults
14 septembre 2026 mis à jour par: David A. Purger
The Effects of Transcutaneous Vagus Nerve Stimulation (tVNS) on Acute Pain Perception and Brain Activity in Healthy Adults
The goal of this clinical trial is to learn whether stimulating a nerve in the neck changes how much pain people feel. It also looks at whether this stimulation changes brain activity. The study is being done in healthy adults ages 18 to 70.
The nerve being studied is called the vagus nerve. It runs through the neck and connects to parts of the brain that handle pain. In this study, the nerve is stimulated from outside the body using a small device placed on the skin. There is no surgery, and nothing is implanted.
The main questions it aims to answer are: (1) Does stimulating the vagus nerve lower the pain people feel during a cold water test? (2) Does stimulating the vagus nerve change the electrical activity in the brain?
Researchers will compare pain ratings and brain activity under three conditions in the same person: no stimulation, real stimulation over the vagus nerve, and sham stimulation placed nearby on the neck. Sham stimulation feels similar but is not aimed at the nerve.
Participants will: (1) Come to one visit that lasts about 90 minutes, with no follow-up visits, (2) Wear a cap that records the brain's natural electrical signals for the whole visit, (3) Place both hands in cold water, about 39 degrees Fahrenheit, up to three times for up to 2 minutes each time, (4) Rate their pain after each cold water test, (5) Wear a stimulation device on the neck during two of the three cold water tests, (6) Not be told which of those two is the real stimulation until the visit is over.
Aperçu de l'étude
Statut
Pas encore de recrutement
Type d'étude
Interventionnel
Inscription (Estimé)
20
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Coordonnées de l'étude
- Nom: Caliel Hines
- Numéro de téléphone: 317-963-7010
- E-mail: calhines@iu.edu
Sauvegarde des contacts de l'étude
- Nom: Marissa Lowe
- E-mail: lowemj@iu.edu
Lieux d'étude
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46202
- IU Health Neuroscience Center
-
Contact:
- Department of Neurological Surgery
- Numéro de téléphone: 317-963-1300
- E-mail: dpurger@iu.edu
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Oui
La description
Inclusion Criteria:
- Adults aged 18 to 70 years
- Healthy, defined as having no history of chronic medical, neurological, or psychiatric conditions
- Not currently experiencing acute illness or chronic pain
- Not currently taking medications that influence the nervous system or pain sensitivity
- Willing and able to provide written informed consent in English
Exclusion Criteria:
- History of vagal or vasovagal symptoms
- Respiratory distress
- Cardiac arrhythmia
- Sleep apnea
- Pregnancy
- Substance abuse
- Primary psychiatric disorder
- Prior vagus nerve stimulation or any implanted medical device
- Significant acute or chronic neurologic illness that, in the judgment of the Principal Investigator, could compromise participant safety, limit the ability to complete the study, or compromise the objectives of the study
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Active Stimulation First, Then Sham
Participants complete a cold pressor test with no stimulation, then a second cold pressor test during active transcutaneous vagus nerve stimulation, then a third during sham stimulation.
|
Stimulation applied over the cervical branch of the vagus nerve, anterior to the sternocleidomastoid along the carotid sheath.
Pulse width 200 microseconds, frequency 30 Hz, rectangular monophasic waveform, intensity titrated between 17.8 and 39.5 volts to a mild tingling sensation below the threshold of discomfort.
Stimulation is maintained for 20 minutes before the cold pressor test and continues throughout it.
Identical device, parameters, and duration as the active condition, differing only in placement.
The device is positioned slightly posterior on the neck, away from the cervical branch of the vagus nerve.
Immersion of both hands up to the wrist in water maintained at 4 degrees Celsius with ice for up to two minutes or as long as tolerated.
Performed three times per participant: once with no stimulation, once during active stimulation, and once during sham stimulation.
|
|
Expérimental: Sham Stimulation First, Then Active
Participants complete a cold pressor test with no stimulation, then a second cold pressor test during sham stimulation, then a third during active transcutaneous vagus nerve stimulation.
|
Stimulation applied over the cervical branch of the vagus nerve, anterior to the sternocleidomastoid along the carotid sheath.
Pulse width 200 microseconds, frequency 30 Hz, rectangular monophasic waveform, intensity titrated between 17.8 and 39.5 volts to a mild tingling sensation below the threshold of discomfort.
Stimulation is maintained for 20 minutes before the cold pressor test and continues throughout it.
Identical device, parameters, and duration as the active condition, differing only in placement.
The device is positioned slightly posterior on the neck, away from the cervical branch of the vagus nerve.
Immersion of both hands up to the wrist in water maintained at 4 degrees Celsius with ice for up to two minutes or as long as tolerated.
Performed three times per participant: once with no stimulation, once during active stimulation, and once during sham stimulation.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Pain intensity measured by the Numerical Pain Rating Scale
Délai: Immediately after each of the three cold pressor tests during a single visit, approximately 90 minutes.
|
Participant-reported pain intensity on an 11-point scale from 0 to 10, where 0 is no pain and 10 is the worst pain imaginable.
Higher scores indicate greater pain.
Rated immediately after each cold pressor test.
|
Immediately after each of the three cold pressor tests during a single visit, approximately 90 minutes.
|
|
Pain intensity measured by the Visual Analogue Scale
Délai: Immediately after each of the three cold pressor tests during a single visit, approximately 90 minutes.
|
Participant-reported pain intensity is marked on a 100 mm line anchored at 0 mm for no pain and 100 mm for the worst imaginable pain.
The distance in millimeters from the left anchor is recorded as the score.
Higher scores indicate greater pain.
Rated immediately after each cold pressor test.
|
Immediately after each of the three cold pressor tests during a single visit, approximately 90 minutes.
|
|
Pain threshold during cold pressor test
Délai: During each of the three cold pressor tests within a single visit, approximately 90 minutes.
|
Time in seconds from hand immersion to the participant's first verbalized sensation of pain, recorded separately for each hand.
|
During each of the three cold pressor tests within a single visit, approximately 90 minutes.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in EEG spectral power
Délai: Continuously throughout a single visit, approximately 90 minutes.
|
Change in spectral power within canonical frequency bands (delta 1 to 4 Hz, theta 4 to 8 Hz, alpha 8 to 12 Hz, beta 13 to 30 Hz, gamma above 30 Hz), measured by continuous 16-channel electroencephalography, compared across resting baseline, stimulation without noxious stimulus, and stimulation during cold pressor test.
|
Continuously throughout a single visit, approximately 90 minutes.
|
|
Change in EEG functional connectivity
Délai: Continuously throughout a single visit, approximately 90 minutes.
|
Change in functional connectivity between brain regions, derived from continuous 16-channel electroencephalography.
Phase locking values are computed for each pair of EEG channels within canonical frequency bands, and connectivity metrics are derived from those values.
Coherence is assessed in the frequency domain.
Analyses are restricted to predefined, theory-driven regions and frequency bands.
Compared across resting baseline, stimulation without noxious stimulus, and stimulation during the cold pressor test.
|
Continuously throughout a single visit, approximately 90 minutes.
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: David A Purger, MD, PhD, Indiana University
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Estimé)
1 septembre 2026
Achèvement primaire (Estimé)
1 janvier 2028
Achèvement de l'étude (Estimé)
1 janvier 2028
Dates d'inscription aux études
Première soumission
14 septembre 2026
Première soumission répondant aux critères de contrôle qualité
14 septembre 2026
Première publication (Réel)
18 septembre 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
18 septembre 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
14 septembre 2026
Dernière vérification
1 septembre 2026
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 27960
- SNEU-IIR-TVNS-ADULTS (Autre identifiant: Indiana University IRB)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
NON
Description du régime IPD
This is a small exploratory pilot study in healthy volunteers, designed to generate preliminary effect size estimates rather than definitive findings.
With a target enrollment of 20 participants at a single site, the dataset is small enough that a decision about sharing individual participant data has been deferred.
The current informed consent form does not specifically address sharing de-identified individual participant data with researchers outside the study team.
Any future data sharing would require review of participant consent and approval by the Indiana University Institutional Review Board.
The study team will revisit this decision before study completion.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Oui
produit fabriqué et exporté des États-Unis.
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .